Anaphylaxis after treatment with recombinant factor VIII: investigation and therapeutic challenge.

Research paper by Sofia S Pires, Teresa T Sevivas, Carla Chaves CC Loureiro, Borja B Bartholomé

Indexed on: 21 Dec '18Published on: 21 Dec '18Published in: BMJ case reports


We report a 10-year-old patient with haemophilia A developing anaphylaxis to recombinant factor VIII (octocog alfa). Allergic reactions, and especially anaphylactic events, are rare in patients with haemophilia A. The nature of these reactions is not fully understood. Here, we demonstrate a type I hypersensitivity reaction using sodium dodecyl sulfate-polyacrylamide gel electrophoresis immunoblotting assay. This test revealed itself as an essential diagnostic tool, as it allowed us to choose an alternative treatment (moroctocog alfa). Its safety was later confirmed by an uneventful challenge test. © BMJ Publishing Group Limited 2018. No commercial re-use. See rights and permissions. Published by BMJ.